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The efficacy and safety of combination therapy with eflornithine and sulindac, as
compared with either drug alone, in delaying disease progression in patients with
familial adenomatous polyposis are unknown.
METHODS

We evaluated the efficacy and safety of the combination of eflornithine and sulindac,
as compared with either drug alone, in adults with familial adenomatous polyposis.
The patients were stratified on the basis of anatomical site with the highest polyp
burden and surgical status; the strata were precolectomy (shortest projected time to
disease progression), rectal or ileal pouch polyposis after colectomy (longest projected time), and duodenal polyposis (intermediate projected time). The patients were
then randomly assigned in a 1:1:1 ratio to receive 750 mg of eflornithine, 150 mg of
sulindac, or both once daily for up to 48 months. The primary end point, assessed
in a time-to-event analysis, was disease progression, defined as a composite of major surgery, endoscopic excision of advanced adenomas, diagnosis of high-grade
dysplasia in the rectum or pouch, or progression of duodenal disease.
RESULTS

A total of 171 patients underwent randomization. Disease progression occurred in
18 of 56 patients (32%) in the eflornithine–sulindac group, 22 of 58 (38%) in the
sulindac group, and 23 of 57 (40%) in the eflornithine group, with a hazard ratio of
0.71 (95% confidence interval [CI], 0.39 to 1.32) for eflornithine–sulindac as compared with sulindac (P = 0.29) and 0.66 (95% CI, 0.36 to 1.24) for eflornithine–
sulindac as compared with eflornithine. Among 37 precolectomy patients, the corresponding values in the treatment groups were 2 of 12 patients (17%), 6 of 13 (46%),
and 5 of 12 (42%) (hazard ratios, 0.30 [95% CI, 0.07 to 1.32] and 0.20 [95% CI, 0.03
to 1.32]); among 34 patients with rectal or ileal pouch polyposis, the values were
4 of 11 patients (36%), 2 of 11 (18%), and 5 of 12 (42%) (hazard ratios, 2.03 [95%
CI, 0.43 to 9.62] and 0.84 [95% CI, 0.24 to 2.90]); and among 100 patients with
duodenal polyposis, the values were 12 of 33 patients (36%), 14 of 34 (41%), and 13
of 33 (39%) (hazard ratios, 0.73 [95% CI, 0.34 to 1.52] and 0.76 [95% CI, 0.35 to
1.64]). Adverse and serious adverse events were similar across the treatment groups.
CONCLUSIONS

In this trial involving patients with familial adenomatous polyposis, the incidence of
disease progression was not significantly lower with the combination of eflornithine
and sulindac than with either drug alone. (Funded by Cancer Prevention Pharmaceuticals; ClinicalTrials.gov number, NCT01483144; EudraCT number, 2012-000427-41.)
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F

amilial adenomatous polyposis is a
rare, autosomal dominant, hereditary
colorectal cancer syndrome that is most
commonly caused by pathogenic germline variants in the adenomatous polyposis coli (APC)
gene.1-3 In its classic presentation, familial adenomatous polyposis is characterized by progressive development of hundreds to thousands of
adenomatous polyps in the lower gastrointestinal tract, mainly in the colon and rectum, and is
associated with up to a 100% lifetime risk of
colorectal cancer if left untreated.1,4 Upper gastrointestinal tract polyposis develops in the duodenum in more than 80% of patients with familial
adenomatous polyposis, and duodenal or periampullary cancer occurs in 5 to 12% of these
patients.5,6 Proctocolectomy is the standard of
care for the management of colorectal polyposis,7 and among patients who had undergone an
initial colectomy and ileorectal anastomosis,
proctectomy with ileal pouch–anal anastomosis
resection is performed in up to 30% because of
progressive polyposis or cancer.8-10 However,
colectomy and proctocolectomy are associated
with complications, including diarrhea, fecal incontinence, and adverse effects on sexual function, fertility, and health-related quality of life.11-15
In the majority of patients with familial adenomatous polyposis, management of duodenal
adenomas is necessary in addition to management of the initial colorectal polyposis16; mesenteric desmoid tumors may also develop in these
patients.15,17 Because surgical and endoscopic
treatment do not completely eliminate the potential for future polyps or extraintestinal neoplasms, there is an unmet medical need for the
identification and use of pharmacologic agents
to delay major endoscopic excisional or surgical
interventions.
Cyclooxygenase (COX) and ornithine decarboxylase (ODC) are enzymes that are normally
negatively regulated by APC and are overexpressed
in tumor tissue.18,19 ODC, the rate-limiting enzyme in the polyamine pathway, and mucosal
polyamine levels are also elevated in polyps in
patients with familial adenomatous polyposis.20
Trials of pharmacologic prevention with nonsteroidal antiinflammatory drugs (NSAIDs) to prevent or delay the progression of polyps in patients with familial adenomatous polyposis or to
prevent the development of advanced adenomas
in patients with sporadic polyps have yielded
limited benefit.21-27 NSAIDs increase polyamine
n engl j med 383;11

catabolism and export through COX-dependent
and COX-independent mechanisms and complement inhibitors of polyamine synthesis to lower
tissue polyamine levels.28
A 3-year randomized, placebo-controlled trial
of a combination of eflornithine, an irreversible
inhibitor of ODC, plus low-dose sulindac for the
prevention of sporadic adenomas showed that
the risk of subsequent advanced colorectal adenomas was more than 90% lower with combination therapy than with placebo.25 Celecoxib,
a COX-2 inhibitor, at a high dosage was briefly
approved for the treatment of familial adenomatous polyposis on the basis of a 28% reduction
from baseline in the mean number of colorectal
polyps in patients in a 6-month trial.29 Although
familial adenomatous polyposis has been removed
from the list of approved uses of celecoxib, treatment with celecoxib and eflornithine enhanced
regression of total polyp burden, as determined
by video-based global assessment.24 These clinical data provide proof of concept that polyamine
inhibition combined with NSAIDs as a potential
approach for pharmacologic prevention could
delay progression of familial adenomatous polyposis. The most important and unmet clinical
needs that could be addressed would be to delay
or avoid surgery or advanced endoscopic resection and to prevent the progression of polyposis.
We conducted a randomized, double-blind,
phase 3 trial to evaluate the efficacy and safety
of a new combination therapy with eflornithine
and sulindac, as compared with either drug
alone, and used a time-to-event analysis with a
composite efficacy end point to determine the
delay in disease progression or major endoscopic or surgical procedures in patients with
familial adenomatous polyposis.

Me thods
Trial Design

The trial was designed by the sponsor, Cancer
Prevention Pharmaceuticals, under the direction
of the last author and in consultation with the
academic authors. The first draft of the manuscript was written by the first four authors and
the last author with the assistance of a medical
writer, in accordance with Good Publication
Practice guidelines, employed by rareLife solutions (funded in part by Cancer Prevention Pharmaceuticals and Mallinckrodt Pharmaceuticals).
The authors were required to give the sponsor 30
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days to review any submissions or publications
to ensure the accuracy of the data, compliance
with regulatory agency requirements, and nondisclosure of intellectual property. The authors
vouch for the accuracy and completeness of the
data and analyses and for fidelity of the trial to
the protocol, available with the full text of this
article at NEJM.org.
The details of the protocol, which was approved by the local institutional review board at
each site of this multinational, multicenter trial,
have been published previously.17 The data and
safety monitoring committee received confidential reports on a periodic basis and was responsible for decisions regarding possible termination
of the trial for either futility or safety reasons.

of

m e dic i n e

tus; the three strata were precolectomy (shortest
projected time), rectal or ileal pouch polyposis
after colectomy (longest projected time), or duodenal polyposis (intermediate projected time).
Randomization

The patients were randomly assigned in a 1:1:1
ratio to receive 750 mg of eflornithine, 150 mg of
sulindac, or both once daily for up to 48 months;
treatment was administered orally as four tablets. The patients in the two monotherapy groups
received a placebo matching the other drug in
the combination. Patients underwent upper and
lower gastrointestinal endoscopy every 6 months
to assess disease status.
End Points

Patients

Adults 18 years of age or older who had clinical
familial adenomatous polyposis and pathogenic
variants of APC were eligible for inclusion in this
trial if they had any of the following endoscopic
findings at baseline: an intact colon with moderate adenoma burden (100 to 1000 polyps) for
which prophylactic surgery was under consideration; a retained rectum or ileal pouch (≥3 years
since ileorectal anastomosis or ileal pouch–anal
anastomosis surgery) with stage 1, 2, or 3 polyposis according to the International Society for
Gastrointestinal Hereditary Tumours (InSiGHT)
classification (stages range from 0 to 4, with
higher stages indicating greater severity of disease) (Table S1 in the Supplementary Appendix,
available at NEJM.org) and excision of any polyp
with a diameter greater than 1 cm at the first
trial-related endoscopy30; or a duodenum with
current stage 3 or 4 polyposis according to the
modified Spigelman duodenal scoring system
and classification or polyposis that had been
down-staged to Spigelman stage 1 or 2 within
the 6-month period before screening (stages
range from 0 to 4, with higher stages indicating
a higher 10-year cumulative risk of duodenal
cancer and a higher frequency of esophagogastroduodenoscopy) (Table S2).31 Patients at high
risk for cardiovascular disease32 or who had
clinically significant hearing loss for which a
hearing aid was used were not eligible. In order
to minimize imbalance among the treatment
groups, the patients were stratified before randomization on the basis of the anatomical site
with the highest polyp burden and surgical sta1030

n engl j med 383;11

The primary efficacy end point, assessed in a
time-to-event analysis, was disease progression,
defined as a composite of major surgery (colectomy, proctocolectomy, duodenal polyp or ampullary excisions, duodenectomy, Whipple procedure,
or pouch or retained rectum resection), excision
of any polyp that was at least 1 cm in diameter
in the retained rectum or pouch, diagnosis of
high-grade dysplasia in the rectum or pouch, or
duodenal disease progression of at least 1 stage
in the Spigelman classification. A secondary efficacy end point, also assessed in a time-to-event
analysis, was disease progression among the
patients in each of the three surgical subgroups.
Patients were monitored for adverse events
and serious adverse events, which were reported
in accordance with National Cancer Institute
Common Terminology Criteria for Adverse Events,
version 4.0.33 An adverse event that occurred during the treatment period was defined as any
adverse event that occurred after the administration of the first dose of a trial drug through 30
days after the last dose was administered. A
treatment-related adverse event was defined as
any adverse event that was considered to be possibly, probably, or definitely related to trial drug,
as determined by the investigator and reviewed
by the medical monitor, both of whom were
unaware of the treatment-group assignments.
Laboratory results were monitored to detect any
safety signals.
Statistical Analysis

The sample-size calculation was based on an expected overall incidence of familial adenomatous
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polyposis–related events of 30% with combination
therapy and 70% with monotherapy over 2 years,
as determined primarily from published literature on the effects of eflornithine or NSAIDs on
polyposis.34 We calculated that we would need to
assign 50 to 55 patients to each treatment group
for the trial to have 85% power to detect a significant difference between eflornithine–sulindac
therapy and monotherapy with either drug, with
a 40 percentage-point lower incidence of familial adenomatous polyposis–related events in the
eflornithine–sulindac group. The time-to-event
analysis of the primary composite end point of
disease progression in the eflornithine–sulindac
group, as compared with either drug alone, was
performed in the intention-to-treat population
with the use of a two-sided stratified log-rank
test at an alpha level of 0.05, and the results were
reported graphically as Kaplan–Meier curves. In
the analysis of the primary composite end point,
data from the patients who were lost to followup were censored at the time their status was
last known. Because the median time to the first
event could not be estimated owing to the small
number of events, the mean time to the first
event was reported as an alternative quantitative
measure. The mean time was estimated as the
area under the curve (the integral of the survival
function). The Proc Lifetest program in SAS statistical software, version 9.4 (SAS Institute), was used
to estimate the mean by summing the rectangular areas under the estimated step function used
with the Kaplan–Meier, Breslow, and Fleming–
Harrington estimators. The mean survival time
was underestimated when the maximum event
time was less than the maximum censored time
in each treatment group.
Continuous data were evaluated with the use
of an analysis of covariance model with treatment as the main effect and the baseline value
and surgical subgroup as covariates. Categorical
data were analyzed with the use of chi-square
tests and the Cochran–Mantel–Haenszel test to
control for subgroup. Ordered categorical data
were analyzed with the use of Kruskal–Wallis
nonparametric tests. Safety was assessed without inferential statistics in all patients who received at least one dose of a trial drug. To control type I error in the primary end-point
analysis, a sequential testing approach was used,
with the primary comparison being between the
eflornithine–sulindac group and the sulindac
n engl j med 383;11

group. If the primary comparison was significant at the 0.05 level, the test proceeded to the
next comparison between the eflornithine–
sulindac group and the eflornithine group.

R e sult s
Patients

A total of 250 patients underwent screening, and
171 underwent randomization — 56 to the
eflornithine–sulindac group, 58 to the sulindac
group, and 57 to the eflornithine group (Fig. 1).
The baseline demographic and clinical characteristics of the patients were similar across the
treatment groups (Table 1).
Primary Efficacy Analysis

The primary composite end point of disease
progression occurred in 18 of 56 patients (32%)
in the eflornithine–sulindac group, 22 of 58
patients (38%) in the sulindac group, and 23 of 57
patients (40%) in the eflornithine group (Table 2).
Kaplan–Meier estimated mean times to the first
event of disease progression in the intention-totreat population were 32.3 months (95% confidence interval [CI], 31.8 to 32.8) in the eflornithine–sulindac group, 23.6 months (95% CI,
23.2 to 23.9) in the sulindac group, and 21.8
months (95% CI, 21.4 to 22.2) in the eflornithine group; the hazard ratio in the eflornithine–
sulindac group, as compared with the sulindac
group, was 0.71 (95% CI, 0.39 to 1.32; P = 0.29),
and the hazard ratio in the eflornithine–sulindac group, as compared with the eflornithine
group, was 0.66 (95% CI, 0.36 to 1.24) (Fig. 2).
Upper or lower gastrointestinal cancer did
not develop in any patient during the trial.
Twelve patients had progression of lower gastrointestinal polyposis (two polypectomies were
performed in the eflornithine–sulindac group,
two colectomies, one proctectomy, and four polyp
ectomies were performed in the sulindac group,
and one pouch resection and two polypectomies
were performed in the eflornithine group). A
total of 14 patients with progression of duodenal
polyposis underwent duodenal surgery (5 in the
eflornithine–sulindac group, 6 in the sulindac
group, and 3 in the eflornithine group) (Table S1).
Disease progression in the duodenum involved
progression in Spigelman stage in 30 patients
and duodenal endoscopic excisional intervention
in 19 patients. Only 8 of the 30 patients with
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250 Patients were assessed for eligibility

79 Were excluded
31 Had minimal disease
11 Had advanced disease
9 Withdrew consent
6 Had abnormal laboratory results
5 Had hearing loss
17 Had other reason

171 Underwent randomization

57 Were assigned to receive eflornithine
plus placebo

Treatment
Extension,
24–48 Mo
(N=63)

56 Were assigned to receive eflornithine
plus sulindac

58 Were assigned to receive sulindac
plus placebo

11 Discontinued treatment
3 Had adverse event
2 Withdrew consent
2 Had protocol violation
4 Were lost to follow-up
22 Had disease progression
3 Underwent colectomy
2 Underwent surgery for polyp
with diameter of ≥1 cm
10 Had progression of ≥1 stage
in Spigelman staging system
1 Underwent proctectomy
4 Underwent pouch resection
2 Underwent duodenal
excision

13 Discontinued treatment
7 Had adverse event
3 Had protocol violation
2 Were lost to follow-up
1 Was withdrawn by physician
15 Had disease progression
1 Underwent surgery for polyp
with diameter of ≥1 cm
10 Had progression of ≥1 stage
in Spigelman staging system
4 Underwent duodenal
excision

14 Discontinued treatment
5 Had adverse event
5 Withdrew consent
3 Had protocol violation
1 Was lost to follow-up
19 Had disease progression
4 Underwent colectomy
3 Underwent surgery for polyp
with diameter of ≥1 cm
6 Had progression of ≥1 stage
in Spigelman staging system
6 Underwent duodenal
excision

8 Did not participate

2 Did not participate

4 Did not participate

16 Were included in treatment extension

26 Were included in treatment extension

21 Were included in treatment extension

13 Completed treatment extension
1 Had disease progression
1 Had progression of ≥1 stage
in Spigelman staging system
2 Discontinued treatment extension
1 Had adverse event
1 Had protocol violation

21 Completed treatment extension
3 Had disease progression
1 Underwent surgery for polyp
with diameter of ≥1 cm
1 Had progression of ≥1 stage
in Spigelman staging system
1 Underwent duodenal excision
3 Discontinued treatment extension
2 Had adverse event
1 Had late familial adenomatous
polyposis–related event

17 Completed treatment extension
3 Had disease progression
1 Underwent surgery for polyp
with diameter of ≥1 cm
1 Had progression of ≥1 stage
in Spigelman staging system
1 Underwent pouch resection
1 Discontinued treatment extension
owing to adverse event

Figure 1. Screening, Randomization, and Follow-up in the Initial Treatment Plan and Treatment Extension.

progression in Spigelman stage underwent inter- event, whereas the remaining 22 patients did not
vention for disease progression or had an addi- have disease progression that was severe enough
tional familial adenomatous polyposis–related for intervention.
1032
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline in the Intention-to-Treat Population.*
Eflornithine–Sulindac
(N = 56)

Characteristic
Male sex — no. (%)

Sulindac
(N = 58)

Eflornithine
(N = 57)

34 (61)

37 (64)

28 (49)

37.8±13.4

38.1±13.7

39.7±14.8

Precolectomy subgroup

27.4±9.7

22.5±3.7

23.2±8.7

Subgroup with rectal or ileal pouch polyposis
after colectomy

38.2±11.6

35.3±11.7

42.4±14.1

Subgroup with duodenal disease

41.5±13.3

44.9±11.4

44.7±12.5

White

48 (86)

50 (86)

54 (95)

Black

6 (11)

3 (5)

1 (2)

Age — yr

Race — no. (%)†

2 (4)

5 (9)

2 (4)

Body-mass index‡

Other

27.2±5.9

27.2±5.4

28.4±7.7

Time since diagnosis — yr

17.4±10.4

15.5±11.4

19.7±11.5

Precolectomy

13 (23)

13 (22)

12 (21)

Colectomy with ileorectal anastomosis

13 (23)

19 (33)

21 (37)

Proctocolectomy with ileal pouch–anal
anastomosis

28 (50)

21 (36)

18 (32)

2 (4)

5 (9)

6 (11)

Surgical status — no. (%)

Colectomy with ileostomy

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.
†	Race was reported by the patients.
‡	The body-mass index is the weight in kilograms divided by the square of the height in meters.

Secondary Efficacy Analyses

The results with respect to the secondary efficacy end point of disease progression among the
patients in the three surgical subgroups are provided in Table 2 and Figure S1. Among the 37 in
the precolectomy subgroup, disease progression
occurred in 2 of 12 (17%) in the eflornithine–
sulindac group, 6 of 13 (46%) in the sulindac
group, and 5 of 12 (42%) in the eflornithine
group. Kaplan–Meier estimated mean times to
the first event of disease progression were 39.3
months (95% CI, 37.1 to 41.6) in the eflornithine–sulindac group, 25.2 months (95% CI,
24.2 to 26.1) in the sulindac group, and 19.7
months (95% CI, 18.2 to 21.1) in the eflornithine
group; the hazard ratio in the eflornithine–sulindac group, as compared with the sulindac group,
was 0.30 (95% CI, 0.07 to 1.32), and the hazard
ratio in the eflornithine–sulindac group, as compared with the eflornithine group, was 0.20
(95% CI, 0.03 to 1.32) (Fig. S1A). There were no
polyposis-related events or surgical procedures
n engl j med 383;11

in the lower gastrointestinal tract among the
patients treated with eflornithine–sulindac in
the precolectomy subgroup.
Among the 34 patients with rectal or ileal
pouch polyposis after colectomy, disease progression occurred in 4 of 11 (36%) in the eflornithine–sulindac group, 2 of 11 (18%) in the sulindac group, and 5 of 12 (42%) in the eflornithine
group. Kaplan–Meier estimated mean times to
first disease progression event were 20.9 months
(95% CI, 19.8 to 22.0) in the eflornithine–sulindac group, 27.5 months (95% CI, 25.3 to 29.6) in
the sulindac group, and 15.7 months (95% CI,
14.9 to 16.6) in the eflornithine group; the hazard ratio in the eflornithine–sulindac group, as
compared with the sulindac group, was 2.03
(95% CI, 0.43 to 9.62), and the hazard ratio in
the eflornithine–sulindac group, as compared
with the eflornithine group, was 0.84 (95% CI,
0.24 to 2.90) (Fig. S1B).
Among the 100 patients with duodenal polyposis, disease progression occurred in 12 of 33
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Table 2. Efficacy Outcomes According to Surgical Subgroup and Treatment Group.*
Eflornithine–
Sulindac
(N = 56)

Subgroup and Outcome

Sulindac
(N = 58)

Eflornithine
(N = 57)

Hazard Ratio for Disease
Progression (95% CI)
Eflornithine–
Sulindac vs.
Sulindac

Eflornithine–
Sulindac vs.
Eflornithine

Precolectomy subgroup
No. of patients

12

13

12

Familial adenomatous polyposis–related event — no. of
patients (%)

2 (17)

6 (46)

5 (42)

Progression of ≥1 stage in Spigelman staging system

2 (17)

1 (8)

2 (17)

Colectomy or proctocolectomy

0

4 (31)

2 (17)

Colectomy or proctocolectomy and progression of ≥1
stage in Spigelman staging system

0

0

1 (8)

Duodenal excision and progression of ≥1 stage in
Spigelman staging system

0

1 (8)

0

0.30 (0.07–1.32) 0.20 (0.03–1.32)

Subgroup with rectal or ileal pouch polyposis after colectomy
No. of patients

11

11

12

Familial adenomatous polyposis–related events — no. of
patients (%)

4 (36)

2 (18)

5 (42)

Progression of ≥1 stage in Spigelman staging system

3 (27)

0

1 (8)

Pouch resection

0

1 (9)

2 (17)

Removal of polyp with diameter of ≥1 cm in rectum or
pouch

0

1 (9)

1 (8)

Proctocolectomy

0

0

1 (8)

Duodenal excision

1 (9)

0

0

2.03 (0.43–9.62) 0.84 (0.24–2.90)

Subgroup with duodenal polyposis
No. of patients

33

34

33

Familial adenomatous polyposis–related events — no. of
patients (%)

12 (36)

14 (41)

13 (39)

Progression in Spigelman stage

5 (15)

3 (9)

7 (21)

Duodenal excision

4 (12)

6 (18)

2 (6)

Duodenal excision and progression of ≥1 stage in
Spigelman staging system

1 (3)

2 (6)

1 (3)

Duodenal excision and removal of polyp with diameter of
≥1 cm in rectum or pouch

0

1 (3)

0

Removal of polyp with diameter of ≥1 cm in rectum or
pouch

2 (6)

1 (3)

1 (3)

Proctocolectomy and removal of polyp with diameter of
≥1 cm in rectum or pouch

0

1 (3)

0

Pouch resection

0

0

2 (6)

0.73 (0.34–1.52) 0.76 (0.35–1.64)

*	The stages in the modified Spigelman duodenal scoring system and classification range from 0 to 4, with higher stages indicating a higher
10-year cumulative risk of duodenal cancer and a higher frequency of esophagogastroduodenoscopy.31 CI denotes confidence interval.

(36%) in the eflornithine–sulindac group, 14 of
34 (41%) in the sulindac group, and 13 of 33
(39%) in the eflornithine group. Kaplan–Meier
estimated mean times to the first event of dis1034
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ease progression were 23.6 months (95% CI,
23.0 to 24.2) in the eflornithine–sulindac group,
21.1 months (95% CI, 20.5 to 21.8) in the sulindac group, and 21.7 months (95% CI, 21.0 to
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Figure 2. Kaplan–Meier Curves for Time to the First Familial Adenomatous Polyposis–Related Event (Intention-to-Treat
Population).

22.3) in the eflornithine group; the hazard ratio
in the eflornithine–sulindac group, as compared
with the sulindac group, was 0.73 (95% CI, 0.34
to 1.52), and the hazard ratio in the eflornithine–sulindac group, as compared with the eflornithine group, was 0.76 (95% CI, 0.35 to 1.64)
(Fig. S1C). The results of each secondary endpoint evaluation is provided in Table S3.

patient each in the sulindac group); and stroke
(in one patient in the eflornithine group). Discontinuation of a trial drug because of adverse
events was reported in nine patients (16%) in the
eflornithine–sulindac group, six patients (10%)
in the sulindac group, and five patients (9%) in
the eflornithine group.

Discussion

Safety

Treatment-related adverse events were reported
by 68% of the patients in the eflornithine–sulindac group, 74% of the patients in the sulindac
group, and 55% of the patients in the eflornithine group (Table 3). Most treatment-related
adverse events were mild to moderate in severity
and resolved with minimal intervention. The most
common treatment-related adverse events reported
among all the patients were nausea (15%), headache (11%), diarrhea (7%), vomiting (7%), rectal
hemorrhage (7%), abdominal pain (7%), flatulence
(6%), dyspepsia (5%), and decreased appetite
(5%). More patients in the eflornithine–sulindac
group than in the monotherapy groups had rash,
upper abdominal pain, and erosive gastritis
(Table 3). The serious treatment-related adverse
events that were reported included acute pancreatitis, nephritis, and psychosis–paranoia (in one
patient each in the eflornithine–sulindac group);
severe nausea, deep-vein thrombosis, worsening
of depression, and spontaneous abortion (in one
n engl j med 383;11

Familial adenomatous polyposis is a systemic
disease, and the ultimate goal of treatment in
patients with this condition is to prevent cancer.
Delaying progression of colorectal and duodenal
polyposis, delaying surgery, and decreasing the
procedure-related morbidity, mortality, and effect
on quality of life11-15 are aspirational. The Colorectal Adenoma/Carcinoma Prevention Programme 1
(CAPP1) trial, in which 133 patients with familial adenomatous polyposis underwent randomization, did not show a benefit of 600 mg of
aspirin, 30 g of fermentable fiber, or both, as
compared with placebo, with regard to polyp
burden.35 Whereas investigators of previous trials
reported polyp burden,21,24-27,29,35 our trial was
designed to detect the incidence of disease progression, which encompasses more than polyposis. In our trial, 171 patients with familial adenomatous polyposis underwent randomization,
and the trial was powered to detect an incidence
of disease progression that was 40 percentage-
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Table 3. Adverse Events with an Incidence of at Least 5% in Any Treatment Group.*
Eflornithine–Sulindac
(N = 56)

Event

Sulindac
(N = 57)

Eflornithine
(N = 56)

Total
(N = 169)

number of patients (percent)
Adverse event that occurred during the treatment period

52 (93)

50 (88)

49 (88)

151 (89)

Treatment-related adverse event

38 (68)

42 (74)

31 (55)

111 (66)

Grade ≥3 adverse event that occurred during the treatment period

12 (21)

12 (21)

17 (30)

41 (24)

Treatment-related serious adverse event

3 (5)

4 (7)

1 (2)

8 (5)

Discontinuation of treatment because of a treatmentrelated adverse event

7 (12)

5 (9)

3 (5)

15 (9)

Death

0

0

0

9 (16)

9 (16)

8 (14)

0

Adverse event of any grade
Nausea

26 (15)

Headache

3 (5)

7 (12)

8 (14)

18 (11)

Diarrhea

4 (7)

3 (5)

5 (9)

12 (7)

Vomiting

2 (4)

4 (7)

5 (9)

11 (7)

Rectal hemorrhage

4 (7)

4 (7)

3 (5)

11 (7)

Abdominal pain

3 (5)

4 (7)

4 (7)

11 (7)

Flatulence

4 (7)

3 (5)

3 (5)

10 (6)

Dyspepsia

2 (4)

4 (7)

3 (5)

9 (5)

Decreased appetite

2 (4)

4 (7)

3 (5)

9 (5)

Abdominal distension

1 (2)

3 (5)

4 (7)

8 (5)

Fatigue

1 (2)

4 (7)

3 (5)

8 (5)

Hematochezia

2 (4)

2 (4)

4 (7)

8 (5)

Upper abdominal pain

5 (9)

1 (2)

2 (4)

8 (5)

Dizziness

2 (4)

2 (4)

3 (5)

7 (4)

Tinnitus

1 (2)

5 (9)

1 (2)

7 (4)

Pruritus

1 (2)

4 (7)

2 (4)

7 (4)

Rash

6 (11)

0

0

6 (4)

Alopecia

2 (4)

3 (5)

0

5 (3)

Thrombocytopenia

0

3 (5)

1 (2)

4 (2)

Depression

0

3 (5)

1 (2)

4 (2)

Frequent bowel movements

0

1 (2)

3 (5)

4 (2)

Erosive gastritis

3 (5)

0

0

3 (2)

*	Adverse events that occurred during the treatment period were defined as any adverse event that occurred after the administration of the
first dose of a trial drug through 30 days after the last dose was administered. A treatment-related adverse event was defined as any adverse
event that was considered to be possibly, probably, or definitely related to trial drug, as determined by the investigator and reviewed by the
medical monitor, both of whom were unaware of the treatment-group assignments. Adverse events were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.33

points lower with the combination therapy than
with monotherapy (the expected overall incidence
of familial adenomatous polyposis–related events
was 30% with combination therapy and 70%
with monotherapy over 2 years). We did not observe that the percentage of patients with dis1036

n engl j med 383;11

ease progression was significantly lower with
combination therapy than with either monotherapy. For ethical reasons, all patients received
a potentially active drug.
To ensure balance in randomization to the
treatment groups, patients were stratified on the
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basis of the anatomical site with the highest
polyp burden and surgical status (precolectomy
[shortest projected time], rectal or ileal pouch
polyposis after colectomy [longest projected
time], or duodenal polyposis [intermediate projected time]). Among the patients in the precolectomy subgroup, those who received the
combination therapy had the lowest incidence
of familial adenomatous polyposis–related
events, with hazard ratios for disease progression of 0.30 (95% CI, 0.07 to 1.32) for the comparison of eflornithine–sulindac with sulindac
and 0.20 (95% CI, 0.03 to 1.32) for the comparison of eflornithine–sulindac with eflornithine.
In this subgroup, no patient who received combination therapy had any gastrointestinal polyposis or underwent lower gastrointestinal tract
surgery. These data show a possible benefit with
combination therapy for patients with familial
adenomatous polyposis who have an intact colon.
The magnitude of the possible benefit of combination therapy with eflornithine and sulindac
observed in this subgroup in our trial is similar
to that reported in a trial involving patients with
sporadic adenomas, in which the same combination therapy provided a significant benefit over
placebo, with a 70% lower risk of metachronous
adenomas and more than a 90% lower risk of advanced adenomas.25 The potential benefit of
combination therapy with eflornithine and an
NSAID to suppress colorectal polyposis is also
supported by the findings in the trial of combination therapy with eflornithine and celecoxib
in patients with familial adenomatous polyposis.24 In that trial, although no significant benefit with combination therapy was observed with
respect to the primary end point (polyp number
in a defined area of the colorectum), substantial
benefit was observed for the secondary end point
of global polyp burden in the whole colon. We
agree with the conclusion by the authors of that
article that this is a more clinically relevant end
point and should have been used as the primary
end point in their trial.
In our trial, there was no observed treatment
benefit with combination therapy in the subgroup of patients who had duodenal polyposis
— the group with an intermediate projected
time to disease progression. The results of the
comparisons between combination therapy and
either monotherapy were not significant in the
subgroup of patients who had rectal or ileal
n engl j med 383;11

pouch polyposis after colectomy — the group
with the longest projected time to disease progression. The percentage of patients with stage
3 severity of disease according to the InSIGHT
classification was greater in the eflornithine–
sulindac group than in either monotherapy group,
which could have affected the outcome; this
possibility suggests that more detailed analyses
of these data may be warranted.
Our trial has several limitations. Despite the
fact that this trial was larger than previous trials
on pharmacologic prevention in patients with
familial adenomatous polyposis, it was relatively
small, and the 95% confidence intervals for our
hazard ratios were wide for this small sample
size. Despite the difficulties associated with
anticipating the incidence of progression among
patients with rare diseases, our data showed that
the eflornithine–sulindac group had the expected
result with an incidence of 32%. However, the
incidences in the eflornithine and sulindac
groups were much lower than the predicted 70%
that we had estimated on the basis of our literature review. This result may have contributed to
the lack of significance between the eflornithine–sulindac group and either monotherapy
group. Furthermore, adult patients who had not
yet undergone a colectomy are difficult to recruit
because most patients with familial adenomatous polyposis are in the need of colectomy by
their late teens.7 Although progression in Spigelman stage was prespecified as an familial adenomatous polyposis–related event and was included
as one of the criteria in the primary composite
end point in this trial, the Spigelman staging
system has not been validated for risk stratification of patients with familial adenomatous polyposis,36 nor is it ideal for this purpose in its current
format.37,38 This point is underscored in a case–
control study involving 18 patients with familial
adenomatous polyposis, among whom duodenal
cancer developed in 9 despite an endoscopic
finding of a Spigelman stage of lower than 4.39
This study also showed that only two components of the scoring system, duodenal adenoma
size and high-grade dysplasia, correlated with
duodenal cancer, which underscores the highly
subjective nature of this scoring system. We
speculate that had the overall change in polyp
burden been our end-point measure, as it has
been in most previous clinical trials, we would
have been able to better capture actual regres-
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sion in adenoma burden. The inclusion of 22
patients who had progression in Spigelman
stage and did not undergo subsequent endoscopic polyp excision or surgery or have an additional familial adenomatous polyposis–related
event may have contributed to a type II error. In
this respect, in the absence of cancer in these
patients, we may have overestimated disease
progression. In our trial, serious adverse events
with the combination therapy with eflornithine
and sulindac up to 4 years were similar to those
with monotherapy, and the majority of adverse
events observed in the trial were mild to moderate in severity.
Our trial did not show that the incidence of
disease progression was significantly lower with
the combination of eflornithine and sulindac
than with either drug alone. No patient with an
intact colon who received combination therapy
underwent surgical intervention. Additional studies that focus on clinical end points in the lower

of

m e dic i n e

gastrointestinal tract are warranted to better
understand the potential of this combination
therapy for pharmacologic prevention in specific
groups of patients with familial adenomatous
polyposis, especially those who have not yet undergone prophylactic colectomy.
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